Company Dashboard

Get the latest news, press releases, earnings, outlook, ratings, and dividends for any company.

Mirum Pharmaceuticals, Inc. ( NASDAQ : MIRM )

Sector: Healthcare | Industry: Biotechnology

Pre-Market	Intra-Day	After-Hours
—	79.96 ( +0.34 / +0.43% )	—
—	14-Oct 16:00	13-Oct 19:04

Previous Close	79.62	52-Week Low	63.23
Open	78.64	52-Week High	130.00
Day Low	78.32	50-Day Average	94.28
Day High	81.86	200-Day Average	98.50
Volume	907.98 K	Market Cap	4.88 B

Stock News

Chart

Press Releases

Analysis

Earnings

Outlooks

Ratings

Dividends

Upcoming Catalysts

Press Releases - MIRM

Latest press releases and announcements for MIRM .

Showing 1 – 5 of 5 press releases for MIRM from 2026-09-08 to 2026-10-12

12-Oct-2026 08:00

MIRM

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.

11-Oct-2026 17:00

MIRM

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum to Host Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases.

28-Sep-2026 08:00

MIRM

Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus.

27-Sep-2026 17:00

MIRM

Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic HDV on September 28, 2026.

08-Sep-2026 08:30

MIRM

Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer

Business Wire

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer.